奧洛茲美醫療 HALO 深 滬
等待開盤 07-24 09:30:00 美东时间
80.15
+2.330
+2.99%
華盛通- 最 高80.22
- 今 開77.43
- 成交量 55.90万股
- 最 低 76.8207
- 昨 收 77.82
- 總市值 950.68万
- 52周最高 82.26
- 市盈率 靜 31.34
- 換手率 471.31%
- 52周最低 58.675
- 委 比 -35.28%
- 總股本 0.00亿
- 歷史最高 82.26
- 量 比 0.55
- 振 幅 4.37%
- 歷史最低 3.86
- 每 手 1
- 風險率 5.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
Halozyme Therapeutics Signs Agreement With Incyte To Mull Additional Subcutaneous Formulations Of INCA033989 Mutant Calreticulin-Targeted Monoclonal Antibody
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targe...
07-20 20:01
Halozyme Appoints David Ramsay as President Drug Delivery
SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, ...
07-01 04:02
As corporate profit margins remain elevated, these mid-caps stand out
With U.S. corporate profit margins remaining near historic highs, investors are increasingly focused on companies that have demonstrated an ability to consistently generate strong earnings and returns...
06-18 21:25
Halozyme Sees Little Royalty Impact From Medicare Drug Pricing Rule, Says CMS Proposal Should Not Hurt ENHANZE Partnerships
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Med...
06-15 18:14
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Halozyme Earnings Call Highlights Royalty-Fueled Growth
Halozyme Therapeutics (($HALO)) has held its Q1 earnings call. Read on for the ...
05-13 08:25
电话会总结 ｜ Halozyme(HALO)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Halozyme业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收：3.77亿美元，同比增长42% - 特许权使用费收入：2.41亿美元，同比增长43%，主要由DARZALEX、VYVGART Hytrulo和PHESGO推动 **盈利能力：** - 调整后EBITDA：2.30亿美元，同比增长超过40% - 调整后EBITDA利润率：约61%（2.30亿/3.77亿） - Non-GAAP每股收益：1.60美元，同比增长44%（从1.11美元增至1.60美元） - GAAP每股收益：1.22美元，同比增长
05-12 12:02
